Treatment of Bone Metastases of Breast Cancer With 177 Lu-DOTA-IBA.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38537210.
- Also identified by DOI 10.1097/RLU.0000000000005193.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bone metastasis of breast cancer often presents as osteolytic. 177 Lu-DOTA-ibandronic acid ( 177 Lu-DOTA-IBA) is a new radioactive drug for bone metastasis lesion. We report a case of recurrent intermittent pain due to bone metastasis, who demonstrated a satisfactory therapy response after 2 cycles of 177 Lu-DOTA-IBA. In addition, the patient did not have any observable adverse effects.
Medical subject headings
- Bone Neoplasms
- Breast Neoplasms